Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cyclophosphamide therapy in pediatric multiple sclerosis.
The refinement of genetic predictors of multiple sclerosis.
Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection.
Assessment and classification of early stage multiple sclerosis with inertial sensors: comparison against clinical measures of disease state.
Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases.
Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States.
Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica.
A hematopoietic contribution to microhemorrhage formation during antiviral CD8 T cell-initiated blood-brain barrier disruption.
Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis.
Breastfeeding is associated with lower risk for multiple sclerosis.
Interferon-β Suppresses Murine Th1 Cell Function in the Absence of Antigen-Presenting Cells.
Personalized Medicine in Neurodegenerative Diseases: How Far Away?
Hormone and immune system interactions in demyelinating disease.
Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy.
Presumptive Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis after Natalizumab Therapy.
Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.
Riluzole inhibits spontaneous Ca2+ signaling in neuroendocrine cells by activation of K+ channels and inhibition of Na+ channels.
Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification.
Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonb therapy in multiple sclerosis.
[Gluten-related disorders and demyelinating diseases.]
Harnessing monocyte-derived macrophages to control central nervous system pathologies: No longer 'if' but 'how'
Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.
Alemtuzumab 3-year data show durable effect on MS disability
Structure and signalling in the IL-17 receptor family.

Pages